Streetbeat News

Earnings

UE

Urban Edge Properties has raised its FY2024 Funds From Operations (FFO) guidance from $1.29-1.32 to $1.32-1.35, surpassing the analyst estimate of $1.32.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:24 am

VRSK

Verisk Analytics has reiterated its fiscal year 2024 outlook, projecting revenues between $2.84 billion and $2.90 billion, compared to the $2.87 billion estimate. The company also expects adjusted EPS to range from $6.30 to $6.60, against a $6.56 estimate.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:23 am

LRMR

Larimar Therapeutics reported a Q3 2024 GAAP EPS of $(0.24), beating the analyst estimate of $(0.39). The company has $203.7M in cash and equivalents.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:21 am

EXTR

Extreme Networks has provided its Q2 FY25 guidance, expecting revenue between $273M-$283M, surpassing estimates of $260.55M. Adjusted EPS is projected at $0.16-$0.20, above the $0.12 estimate. For FY25, revenue is expected to be $1.117B-$1.137B, slightly above the $1.12B estimate.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:20 am

VRSK

Verisk Analytics reported Q3 2024 earnings per share of $1.67, surpassing the expected $1.60. However, their sales of $725.3 million fell short of the $722.167 million estimate. Despite the sales miss, this represents a significant increase from last year's $677.6 million.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:19 am

ACMR

ACM Research announced preliminary unaudited revenue for Q3 2024, ranging from $200M to $203M, marking a 19% to 20% increase.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:19 am

REYN

Reynolds Consumer Products has released its Q4 2024 financial outlook, expecting net revenues between $945M and $985M, and adjusted EPS between $0.56 and $0.60, surpassing previous estimates.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:18 am

BLKB

Blackbaud reported its Q3 2024 financial results, with adjusted EPS of $0.99 missing the estimate of $1.07, and sales of $286.727 million falling short of the $293.780 million estimate.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:16 am

MNRO

Monro reported its Q2 2025 financial results, with adjusted EPS of $0.17 missing the estimate of $0.26, while sales of $301.391 million slightly beat the estimate of $300.059 million.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:16 am

NBIX

Neurocrine Biosciences shares rose following strong Q3 results, an increased annual revenue outlook for valbenazine, and a $300 million stock buyback authorization.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:15 am